


Please type a plus sign (+) inside this box → ☐

PTO/SB/08 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/726,148
				Filing Date	December 2, 2003
				First Named Inventor	Yoshimura et al.
				Group Art Unit	1652
				Examiner Name	Monshipouri, M.
Sheet	1	of	1	Attorney Docket Number	PF613TD1

U.S. PATENT DOCUMENTS						
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
M. E.	AA	5,990,293		Docherty et al.	11-23-1999	

FOREIGN PATENT DOCUMENTS								
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
M.E.	AB	WO	97/09430		Celltech Therapeutics Ltd.	03-13-1997		

OTHER REFERENCES - NON PATENT LITERATURE DOCUMENTS					
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
M.E.	AC	GENBANK Accession No. A61275, "Sequence 1 from Patent WO9709430," (March 1998).			
M.E.	AD	HITE, et al., "Sequence of a cDNA clone encoding the zinc metalloprotease hemorrhagic toxin e from Crotalus atrox: Evidence for signal, zymogen and disintegrin-like structures," <i>Biochemistry</i> 31:6203-6211 (1992).			
M.M.	AE	HOWARD, et al., "Molecular cloning of MADM: a catalytically active mammalian disintegrin-metalloprotease expressed in various cell types," <i>Biochem. J.</i> 317:45-50 (1996).			
M.M.	AF	KRATZSCHMAR, et al., "Metargidin, a membrane-anchored metalloprotease-disintegrin protein with an RGD integrin binding sequence," <i>J. Biol. Chem.</i> 271(9):4593-4596 (1996).			
M.E.	AG	PAINE, M.J.I. et al., "Cloning of metalloprotease genes in the carpet viper ( <i>Echis pyramidum leakeyi</i> ): Further members of the metalloprotease/disintegrin gene family," <i>Eur. J. Biochem.</i> 224:483-488 (1994).			
M.M.	AH	WOLFSBERG, T.J. et al., "ADAM, a novel family of membrane proteins containing a disintegrin and metalloprotease domain: Multipotential functions in cell-cell and cell-matrix interactions," <i>J. Cell Biol.</i> 131:275-278 (1995).			

Examiner Signature	<i>M. Monshipouri</i>	Date Considered	7/7/04
-----------------------	-----------------------	--------------------	--------

\* Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIP Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.